Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Non-Current Debt (2023 - 2025)

Kura Oncology (KURA) has disclosed Non-Current Debt for 3 consecutive years, with $9.7 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt rose 40.41% to $9.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.7 million through Dec 2025, up 40.41% year-over-year, with the annual reading at $9.7 million for FY2025, 40.41% up from the prior year.
  • Non-Current Debt for Q4 2025 was $9.7 million at Kura Oncology, up from $5.3 million in the prior quarter.
  • The five-year high for Non-Current Debt was $9.7 million in Q4 2025, with the low at $5.3 million in Q3 2025.
  • Average Non-Current Debt over 3 years is $8.2 million, with a median of $8.9 million recorded in 2023.
  • Peak annual rise in Non-Current Debt hit 40.41% in 2025, while the deepest fall reached 31.21% in 2025.
  • Over 3 years, Non-Current Debt stood at $9.3 million in 2023, then decreased by 25.89% to $6.9 million in 2024, then soared by 40.41% to $9.7 million in 2025.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $9.7 million, $5.3 million, and $6.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.